EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Human tumors retain sensitivity to AG3340, a selective metalloprotease inhibitor, after extended treatment and serial passage in vivo



Human tumors retain sensitivity to AG3340, a selective metalloprotease inhibitor, after extended treatment and serial passage in vivo



Proceedings of the American Association for Cancer Research Annual Meeting 40: 709, March




(PDF emailed within 1 workday: $29.90)

Accession: 035055843

Download citation: RISBibTeXText



Related references

Evaluation of long-term effects of intraocular injections of AG3340, a selective matrix metalloprotease inhibitor. IOVS 40(4): S172, March 15, 1999

Efficacy of Prinomastat) (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization. Current Eye Research 24(1): 33-38, 2002

Marked inhibition of the proliferation of human adenocarcinoma colon tumors in vivo by orally-administered AG3340, a novel matrix metallo-proteinase inhibitor. Proceedings of the American Association for Cancer Research Annual Meeting 39: 302, March, 1998

AG3340, a selective MMP inhibitor, has broad antiangiogenic activity across oncology and ophthalmology models in vivo. Proceedings of the American Association for Cancer Research Annual Meeting 40: 66, March, 1999

Randomized, Double-Blind Phase II Study of the Matrix Metalloprotease Inhibitor, AG3340 in Patients with Myelodysplastic Syndrome. Blood 100(11): Abstract No 3119, November 16, 2002

Increased apoptosis in human androgen-independent prostatic PC-3 tumors following oral administration of a novel matrix metalloproteinase inhibitor, AG3340, in male nude mice. Proceedings of the American Association for Cancer Research Annual Meeting 39: 646, March, 1998

Intraocular properties of AG3340, a selective matrix metalloproteinases inhibitor with antiangiogenic activity. IOVS 39(4): S585, March 15, 1998

Efficacy of AG3340, a selective inhibitor of matrix metalloproteases in an animal model of retinal neovascularization. IOVS 40(4): S617, March 15, 1999

Ocular pharmacokinetics of AG3340, a selective inhibitor of matrix metalloproteases , following repeated oral administration. IOVS 40(4): S86, March 15, 1999

Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediatric Hematology and Oncology 17(8): 635-650, 2000

Serial passage of human tumors in chick embryo: growth inhibition by nitrogen mustard. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine 87(1): 223-227, 1954

Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Annals of the New York Academy of Sciences 878: 236-270, 1999

Growth characteristics of human colo rectal tumors during serial passage in immune deprived mice/. British Journal of Cancer 37(2): 213-223, 1978

In vivo administration of nimesulide, a selective PGHS-2 inhibitor, increases in vitro myometrial sensitivity to prostaglandins while lowering sensitivity to oxytocin. Journal of the Society for Gynecologic Investigation 5(6): 296-299, 1998